Bank Julius Baer & Co. Ltd, Zurich Actinium Pharmaceuticals, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$4.57 - $6.4 $13,837 - $19,379	-3,028 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$6.01 - $8.8 $34,888 - $51,084	-5,805 Reduced 65.72%	3,028 $18,000
Q3 2021 Nov 12, 2021	BUY	$5.76 - $9.67 $29,030 - $48,736	5,040 Added 132.88%	8,833 $78,000
Q2 2021 Jul 23, 2021	BUY	$7.01 - $8.63 $6,624 - $8,155	945 Added 33.18%	3,793 $30,000
Q1 2021 May 10, 2021	SELL	$7.62 - $9.79 $9,563 - $12,286	-1,255 Reduced 30.59%	2,848 $22,000

Q4 2020 Feb 24, 2021	BUY	$7.8 - $12.64 $17,893 - $28,996	2,294 Added 126.81%	4,103 $32,000
Q4 2020 Feb 12, 2021	SELL	$7.8 - $12.64 $25,911 - $41,990	-3,322 Reduced 64.74%	1,809 $32,000
Q3 2020 Nov 10, 2020	BUY	$7.26 - $18.0 $37,251 - $92,358	5,131 New	5,131 $50,000

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.